Kathleen McTigue
Pittsburgh, PANPI 1184698946
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $224,255 of the $224,795 with a category attached, or 99.8%. Pfizer accounts for 99.8% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $71,155, more than ten times the $13 reported in 2019.
Across 34 payments — averaging $6611.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$224K
- Journey Medical Corporation$214
- Johnson & Johnson$166
- Lilly USA, LLC$106
- Novartis$33
- LEO Pharma Inc.$21
Across 31 payments — averaging $61,513 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.9M
What the payments were for
- Consulting fees$224,255100%
- Food & beverage$5400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 12 | $224,255 |
| Journey Medical Corporation | 1 | $214 |
| Johnson & Johnson | 11 | $166 |
| Lilly USA, LLC | 7 | $106 |
| Novartis | 2 | $33 |
| LEO Pharma Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Targadox$214
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.